XML 69 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 27, 2017
Mar. 31, 2018
Apr. 01, 2017
Dec. 31, 2020
Dec. 31, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Cash proceeds from divestiture of businesses   $ 1,300,000 $ 25,300,000      
Change in financial assets   (9,600,000) 17,100,000      
Transfers among level 1, 2, and 3   0       $ 0
Net gain on reduction of contingent consideration     16,500,000      
Loss on contingent consideration     2,100,000      
Measured on a recurring basis | Level 3            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Decrease in fair value of milestone payment   (9,600,000)        
Royalty Pharma Contingent Milestone Payments | Measured on a recurring basis | Level 3            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Potential contingent milestone payments   124,900,000 184,500,000     134,500,000
Decrease in fair value of milestone payment   9,600,000        
Estimated fair valued contingent milestone payment   $ 124,900,000       $ 134,500,000
Scenario, Forecast            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Potential contingent milestone payments       $ 56,700,000 $ 68,200,000  
Fair value adjustment       400,000,000 250,000,000  
Change in financial assets       343,800,000 181,800,000  
Net sales threshold for milestone payment       $ 1,950,000,000 $ 1,850,000,000  
Specialty Sciences            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Gain related to Royalty Pharma     $ 17,100,000      
Royalty Pharma            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Sale price of divestiture - cash plus non-cash $ 2,850,000,000          
Cash proceeds from divestiture of businesses 2,200,000,000          
2018 milestone payment 250,000,000          
2020 milestone payment $ 400,000,000          
Volatility rate   30.00%        
Rate of return   8.08%